



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6/Q
220740
10-13-01
RECEIVED
SEP 27 2001
TECH CENTER 160012500

In re Application of:

Lollar


: Group Art Unit: 1653

Serial No.: 09/435,403

: Examiner: H. Schnizer

Filed: November 5, 1999

For: GLYCOSYLATED, LOW
ANTIGENICITY, LOW
IMMUNOGENICITY FACTOR VIII



RESPONSE TO OFFICE ACTION AND AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action dated March 12, 2001, Applicants respectfully request reconsideration of the rejection and entry of this Amendment.

In the Specification:

Please replace the second paragraph at page 1 with the following:

a,
Hemophilia A is defined as hereditary deficiency of blood coagulation fVIII. fVIII is synthesized as a ≈ 300 kDa single chain protein with internal sequence homology that defines the "domain" sequence $\text{NH}_2\text{-A1-A2-B-A3-C1-C2-COOH}$ (Fig. 1). Domains are commonly delineated as A1 (Ala1-Arg372), A2 (Ser373-Arg740), B (Ser741-Arg1648), and A3-C1-C2 (Ser1690-Tyr2332). Despite its large size, the B domain of fVIII has no known function and can be deleted. fVIII is